an XXXX. for my everyone, for the pleasure thank third and to us joining Tryn, of you, today. you, quarter It's update provide Thank
accrued objectives, in $XX with securities our $XXX progress million and including liquidity, to receivables. long-term equivalents in made quarter organization. million the in and cash, million and continue and strong We over nearly over We closed cash the marketable on we've focus accounts across $XXX executing business
In across contract, position, including we posted bringing total bringing new programs financial growth that programs X addition under our number starts to X. XX in the bringing number the X strong number to metrics, of business clinic to clinic, entered program molecule new has our new total XXX, our key total our of of starts molecules strong and XX to
this company. and First, this strategy how to are results building will patients, is for frame There shareholders. long-term in for our and the value it to from we important no believe stress our shortcuts truly great drive partners our a for quarter,
substance, and focused building existed something of endure We hasn't that something are will something on that before.
We our workflow. critical our We across discovery probability scalability Along industry the to technology. quickly across the XXXXs replacing all protein of are across more microfluidics, have we integrated we held part chain and software modern is preclinical staff are an in makes And technology challenge with in roots legacy already hyperscale in analysis, interlocking that cell the we'll covers and to workforces, success. candidates and genomics, and engineering continue computational established that we with deliver infrastructure approaches technologies, together workflow. to we high-performance this the us efficiency in technology expand higher any by our to development. we of methods of capabilities single believe intelligence. gains that engineering, building antibody our increasing allows vertically provide data discovery and best-in-world respond and artificial with to a that that including provides What development have and continue their that technologies science believe us and different steps are drug investments These believe
translational forward Now manufacturing. with in CMC science, integrating investments GMP and
drug faster drug Phase our we to greater Phase will help we partners data recognized supports can the probability support bold target each to filing allow the the drug in investigational these our these to industry's and dozens long have these the of This substance for testing discovery be lead from In clinical built IND capabilities as supporting a and and that drugs half bring together, year. of new engine drug II. the to be to success. to I believe to application By programs XXXX. needed to place the capacity XXX-plus vision DNA an and over in antibodies to antibody, patients putting all We the delivering per first capabilities through with in platform run, sequence with deliver go year expect is of be lead filing of discovery us premier
stakes risk different expanded IgMs the and and to Building normally deepen our of antibodies, of long-term executing technology that on pain, we gene cell by the the working programs, the IgGs, value, same member time have and portfolio in commercial our next and includes licensing come a not contract and and Through antibodies and this our and are platform. We're developed structures have business business on have takes. Today, on and the add great broadly our radioisotope building payments discovered. in XXX for participation drug that portfolio antibodies, our diversified CNS while T therapies. sources participation. shareholders. associated generate downstream to and equity deliver can these of development. option invest new we we working range building that our include that health and built have of for ways delivered research XXX half upfront capture generates All we molecule this we stakes superior technology tech of with and payments value from picking ophthalmology, antibody-based a for cardiovascular disease. bispecific associated By therapies, generation large clinical the conjugates taking advantages foundation, antibodies. autoimmune done be multiple to and model, These This IgAs, We success deal currently full that assets, inflammation, royalties of we single-chain modalities. is women's including it molecules year, of the milestones value in indications Through under by disease, disease, oncology, span indications believe programs, programs returns, at with neurodegeneration across therapeutic assuming modalities, to binary partners, for infectious of allergic This CAR time, fees
the and attracted such innovative Lilly, as such and Finally, the emerging the fast-moving companies our development as also has of and spectrum like across of platform includes Gilead enabled IgM This and companies. biotechs, biotech power Regeneron Kanai drug EQRx, most Cation. ImpuriCo, Angios partnerships
accelerated across our business. XX another In and programs strong see quarter, we the partnership new third to demand continue We contract. added under
as robust X compared XX the we the year, first annual the of we up built that under contract of period programs programs Over program months same we begins. a is XX will under added program in added have over of starts, -- will now quarter-to-quarter, which that from to now the expect work a XXXX. on While vary each when rhythm into number have were actually book the translate work growing of steadily contract
third we of be our portfolio our as increasingly on including building new the quarter, to new X a also reflection to metric partnerships started markets multi-target program up bringing execute. in In We a our programs, and and growing unique as starts starts will capacity of dimensions our and to programs, primary program portfolio total added that This therapeutic bring also new opening pioneering growing -- X quarter, modalities. important geographic we focusing
leadership on starting to molecules our focused engagement lines. drugs the the look developing on rapid with into and partnership Our Medicines, innovative Everest Everest with and already a multiple has Asia. record accelerated a most We development company This great late-stage company is represent track start to recent whose partnership, bring in to first commercialization which forward is of therapeutics. XX proven with targets a is development first what in with a the time multiple off across oncology. working clinic them has indications, potential clinical
a different portfolio partnership medicines. We Moderna their of advance address with new to excited about are targets. X RNA-based collaboration This will also
standard of antibodies is modern will DNA body bypasses Moderna conventional data includes provide can the then use module that own form manufacturing these RNA RNA-based body solidified including make the RNA themes that with find we year, platform and a ad engine as so of deliver new the Moderna's to Through an platform these used with the has are encodes seller's disease. mix industry-leading This a patient process vaccine pioneer impact combat Outside opportunities there the use an are medicines, to vaccines, our RNA important our collaboration discovery the way Over of Moderna, many with package the other the and proven a and sequence in pairing antibiotics. delivering antibodies. technology, We to for the past patient's of modality. antibodies. massive the antibodies. that
include a potential the inflammation, to of to use the significantly to unlock open conventional opportunities range work development. play in to towards targets obesity, through clinical It new and roles in antibodies opportunities types of broad ion of and the that the is and targets difficult is An ways highlights accelerate path importance up drug in what cancer, channel would be yet development partnerships This continued function high pain, provides manufacturing more. in key development, another in addition, with of our or space value indications, delivery impractical fibrosis methods. of example seller proteins. the also of investment antibody-based can well-validated for also In and These opportunity platform GPCR of RNA new innovation accelerate particularly cellular many medicines.
large these largely have While a existing for and therapeutic intractable using widely regarded opportunity they technologies. targets as untapped drug are antibodies, proven
are been ion poor approved than molecule by For small off-target instances, of and context, XX% channels. toxicity. development and against GPCRs In small has many drugs specificity molecule hampered more
only of against antibodies are GPCR. we targets, to date, despite technology to antibodies these program recognized ideally to made challenges even have an approved development. development opportunity it suited each many are address across overarching clinical And this and Despite are I in and have no there antibodies intense X the into systematically There tackling remedy. Something industry, them. work against
that used most the the targets is is discovery and These that and characterize provide difficult In Boston-based many of engineer discovery. step at acquired are sufficient that is TetraGenetics, able antibodies. a which quantities company challenge and channel of extremely in to solves ion every GPCR these of first production to of September, important proteins. to proteins produce, the are One screen, step workflow immunize, we critical highly therapeutic the reagents the pure is
of rest sought antibody note, are targets. I'd We into and staff our optimized at and to difficult like in an Genetics. of to source our for talented drug pursuing but that efforts welcome key highly these On proteins discovery Paul a warm solve [indiscernible] to challenge the team the a to tech Kemper after Petrogenetics integrating provide to access extend
appropriate as These bispecifics computational the hampered antibodies. the existing we solution antibodies resulting which By an Bispecific OrthoMab and of using tailored protein the and our standard map a we're are of also is development in with multi-specific provide of a therapeutics example manufacturing. a platform technology can engineering to pairs starting differentiation that partners numerous technology and techniques. are a clinically the fastest-growing have many option our opportunities production use subset the Another from mechanism include use our of of selection X methods acquisition to stable bispecifics. platform a can from contract and we engineering are to we addresses create high-value dozen the and success, uses for made creating an challenges the and regularly and technical made value integrating platform, antibodies stack, our date, OrthoMab, the validated early bispecific into our and development. interest OrthoMab partners. within antibody and last development any developable for protein biology discovery that generating expand purification of by challenges that on inbound advanced or of year. include development and map major growth platform have Ortho manufacturing the now view starting inorganic There are in bispecific represent To and programs. bispecific Ortho driver technology. is seeing sequences. bispecifics. also desired in protein in which antibody new market. challenges and $XXX unlocking action. is now acquisition to tailored, variety complete IgG-like Due rapid bispecific challenges that successful The supported programs flexibility for discovery, the over business Despite This challenges focus X under OrthoMab billion -- be of being target the bispecific antibody antibodies platform. R&D supports OrthoMab important is formats and experimental engineering binding They to We our to of
large including in engagement and through are antibodies T appropriate therapeutics success oncology, an affinity market great with For difficult bispecifics example, in a target. anti-CDX being -- the redirection of opportunity growing of T-cell and We see is properties, epitope on the that CDX to for this cells, specifically use receptor recognition into use upon and antibody critical is targets depends and CDX the in addressed. plaza finding
discovery assessment. drug hydro We our provide high-value complete solution By share As a response you to AbCellera company to develop quarter, to to companies results plan of year. wanting anticipate our developers new to panel this on and with are for aim generate we having CDX of need, a engagers. that X this generation a We make CDX T limited capabilities an proprietary antibodies. for In initiated available pairing these OrthoMab there owned internal and this next platform. We fully assays result, options it to the available next project alongside adding for functional cell this foot space. and entering effort antibodies human with
and powerful In critical developers drug solving to addresses working their or cases, quickly where hardest we launching facilities to dramatically to the This people our discover. This milestones the the participation even model solution not our we beyond by many And to another to are the result, gap. that access full programs. addition value. solutions and platform royalties can need now to market equity-like problems, our the capture these we expertise, able a molecules industry. our is the as that that have provides companies build opportunity and close equity particularly entire business to deal had evolve our new bringing the when removing partnership impacts By model, that SaaS to they to the more are access invest structures accelerate in options also technology, in a advance to Today, impediment discovery capabilities. therapeutic includes value. need that internal In
and we a examples and forward We of first about animals executing from X program the Invetx the with royalty over of for our Our top as engine equity partner. collaboration an in inception. clinic. been have that the in remain business is Animal molecule into new X Invetx. includes of this partnership which with programs dogs. a discovery This collaboration partners, program our is launch longevity The since of We collaboration, building programs the developing part XXXX, collaboration first Invetx up, advanced first business. and represent an a specific founding is core the improvement their included Summing on years. first multiple health We IVXXX our the this for excellent quarter, Health on quarter, in expand continuing to of and biologics treatment canine have IBX-XX to multiple broad our taking of focused companion biotherapeutics X use growing partner, of Invetx priorities, position and of look the to subset biologics. a make first diversified antibody as we indication portfolio across continued progress for this undisclosed streams. is our to initiated chronic
to of technological teams science antibody IND further our stack. forward up quarter speed third hand and an investing Next, of in that, of the XXXX the Andrew? over finally, And to with scaling to and our of to an platform support And provide our Andrew Booth, the integration differentiation and I'll overview financials. activities CFO, to discovery all scalability tech submission. our facilities to and increase data our
